Is Arcturus Therapeutics Holdings Inc. (ARCT) a Buy, Sell, or Hold?
Arcturus Therapeutics Holdings Inc.
NASDAQ:ARCT
$6.37 USD
-$0.34 (-5.07%)
- Volume
- 651.13K
- Average Volume
- 443.56K
- Market Capitalization
- $181.05M
- P/E Ratio
- -2.25
- Dividend Yield
- 0.00%
- Price Target
- $22.50
- Year High
- $24.17
- Year Low
- $5.85
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $6.31
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Joseph E. Payne |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ARCT |
| CUSIP | 03969T109 |
| CIK | 0001768224 |
| Web | https://arcturusrx.com |
| Phone | 858 900 2660 |
| Currency | USD |
| Employees | 111 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.13 |
| Payout Ratio | 0.00 |
| Current Ratio | 6.31 |
| Quick Ratio | 6.31 |
| Cash Ratio | 6.15 |
Sales & Book Value
| Annual Sales | $67.22M |
| Price / Sales | 3.99 |
| Cash Flow | -2.07 |
| Price / Cash Flow | -3.07 |
| Price / Book | 0.95 |
Price Target and Rating
| Average Stock Price Forecast | $22.50 |
| High Stock Price Forecast | $25.00 |
| Low Stock Price Forecast | $20.00 |
| Forecast Upside/Downside | -71.69% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 21 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-2.4 |
| Trailing P/E Ratio | -2.25 |
| PEG Ratio | 0.14 |
| P/E Growth | 0.14 |
| Net Income | $-65.78M |
| Net Margin | -173.47% |
| Pretax Margin | -173.47% |
| Return on Equity | -36.55% |
| Return on Assets | -32.06% |
Financials Score
| AltmanZ Score | -0.84 |
| Piotroski Score | 2.00 |
| Working Capital | 182.51M |
| Total Assets | 245.41M |
| Ebit | -70.41M |
| Market Cap | 190.72M |
| Total Liabilities | 54.05M |
Poll Results
About Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Stock
Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on RNA-based medicines, developing a pipeline of vaccines for infectious diseases alongside treatments for rare liver and respiratory conditions across the United States. Its notable development programs encompass LUNAR-OTC, designed for ornithine transcarbamylase (OTC) deficiency, and LUNAR-CF, targeting cystic fibrosis lung disease caused by specific CFTR gene mutations. The company also advances vaccine initiatives such as LUNAR-COV19 and LUNAR-FLU. Arcturus has cultivated a range of strategic collaborations, including partnerships with Vinbiocare Biotechnology Joint Stock Company for manufacturing COVID-19 vaccines; Janssen Pharmaceuticals, Inc., to create nucleic acid-based therapies for hepatitis B virus; Ultragen ... yx Pharmaceutical, Inc., for developing mRNA therapeutics aimed at rare disease targets; CureVac AG, to progress mRNA therapeutic and vaccine candidates across various indications; the Singapore Economic Development Board and Duke-NUS Medical School, specifically for the LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc., focused on discovering siRNA medicines for non-alcoholic steatohepatitis (NASH). Founded in 2013, Arcturus Therapeutics maintains its corporate headquarters in San Diego, California.
Arcturus Therapeutics (ARCT) Stock Jumps 5.7%: Will It Continue to Soar?
2026-07-03 08:12:13
Arcturus Therapeutics (ARCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Arcturus Picks Thermo Fisher To Support Cystic Fibrosis Therapy
2026-07-02 11:32:58
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is collaborating with Thermo Fisher Scientific Inc. (NYSE:TMO) to support the Phase 3 development and potential commercialization of ARCT-032, the company's investigational messenger RNA therapy for cystic fibrosis.
2026-07-02 08:00:00
Arcturus Therapeutics Holdings Inc. (âArcturusâ, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare
2026-07-02 07:00:00
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (“Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced a strategic collaboration with Thermo Fisher Scientific, the world leader in serving science, to help support the Phase 3 development and potential commercialization of ARCT-032, Arcturus' investigational mRNA therapy for Cystic Fibrosis. The collaboration will leverage Thermo.
Arcturus could halve the grid's electrical losses using its nano-infused copper
2026-06-30 11:01:42
The world uses a lot of copper, but thanks to the energy transition and data centers, it'll need a lot more. Between now and 2050, we'll have to produce more copper than has been mined throughout all of human history, according to one study.
Arcturus Therapeutics Holdings Inc. (ARCT) Shareholder/Analyst Call Prepared Remarks Transcript
2026-06-05 13:42:56
Arcturus Therapeutics Holdings Inc. (ARCT) Shareholder/Analyst Call Prepared Remarks Transcript
Arcturus Therapeutics Highlights mRNA Pipeline, CF Data and Vaccine Expansion at Jefferies
2026-06-05 05:03:36
Arcturus Therapeutics NASDAQ: ARCT President and CEO Joseph Payne outlined the company's messenger RNA programs, vaccine approvals and upcoming clinical milestones during a presentation at the Jefferies Global Healthcare Conference in New York.
Arcturus Therapeutics to Present at 2026 Jefferies Global Healthcare Conference
2026-05-26 16:01:00
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics will present at 2026 Jefferies Global Healthcare Conference.
Frequently Asked Questions
-
What is the current Arcturus Therapeutics Holdings Inc. (ARCT) stock price?
-
Arcturus Therapeutics Holdings Inc.(NASDAQ:ARCT) stock price is $6.37 in the last trading session. During the trading session, ARCT stock reached the peak price of $24.17 while $5.85 was the lowest point it dropped to. The percentage change in ARCT stock occurred in the recent session was --5.07% while the dollar amount for the price change in ARCT stock was -$-0.34.
-
ARCT's industry and sector of operation?
-
The NASDAQ listed ARCT is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ARCT?
-
Alan H. Cohen FAAAAI FAAP FACAAI FCCP | Chief Medical Officer
Ye Zhang | Chief Regulatory & Quality Assurance Officer
Kevin T. Skol | Chief Business Officer
Dennis Mulroy | Chief Financial Officer
Igor Smolenov | Chief Development Officer -
How many employees does ARCT have?
-
Number of ARCT employees currently stands at 111. ARCT operates from 10628 Science Center Drive, San Diego, CA 92121, US.
-
Link for ARCT official website?
-
Official Website of ARCT is: https://arcturusrx.com
-
How do I contact ARCT?
-
ARCT could be contacted at phone #858 900 2660 and can also be accessed through its website. ARCT operates from 10628 Science Center Drive, San Diego, CA 92121, US.
-
How many shares of ARCT are traded daily?
-
The average number of ARCT shares traded daily for last 3 months was 443.56K.
-
What is the market cap of ARCT currently?
-
The market value of ARCT currently stands at $181.05M with its latest stock price at $6.37